N
ATRS

Natixis’s Antares Pharma, Inc. ATRS Stock Holding History

Natixis’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,901
Closed -$58K – 1263
2017
Q3 		$58K Buy
+17,901
New +$55.2K ﹤0.01% 1207

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Natixis's ATRS Position: Q4 2017 in Review

Natixis sold out of Antares Pharma, Inc. (ATRS) in Q4 2017, closing a stake of 17,901 shares — an estimated $58K sold.

Natixis first reported a position in ATRS in Q3 2017 and held it in 1 quarter. The position peaked at $58K in Q3 2017. 110 funds tracked by Wall St. Rank hold ATRS as of Q4 2017.

  • Natixis reported no remaining Antares Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Natixis sold 17,901 Antares Pharma, Inc. shares in Q4 2017, an estimated $58K.
  • Natixis first reported a position in Antares Pharma, Inc. in Q3 2017 and held it in 1 quarter.
  • Natixis's Antares Pharma, Inc. position peaked at $58K in Q3 2017.
  • 110 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2017.

Based on Natixis's 13F filing for Q4 2017, filed 14 Feb 2018.